Retreatment with sofosbuvir plus grazoprevir plus elbasvir plus ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir plus ledipasvir or plus daclatasvir or plus simeprevir regimen (ANRS HC34 REVENGE study)
Victor De Ledinghen
,
Claire Laforest
,
Christophe Hézode
,
Stanislas Pol
,
Alain Renault
et al.
Hepatology , 2017, 64 (6), pp.1130A--1130A
Journal articles
hal-01487921v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
ABO blood group does not influence Child‐Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts
Isabelle Ollivier-Hourmand
,
Yohann Repesse
,
Pierre Nahon
,
Cendrine Chaffaut
,
Thông Dao
et al.
Journal articles
hal-03553907v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Christophe Hézode
,
Hélène Fontaine
,
Céline Dorival
,
Fabien Zoulim
,
Dominique Larrey
et al.
Journal articles
inserm-01057763v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather
S. Pol
,
M. Bourlière
,
S. Lucier
,
V. de Ledinghen
,
F. Zoulim
et al.
The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver , Apr 2015, Vienne, Austria. pp.S258--S259,
⟨10.1016/S0168-8278(15)30149-5⟩
Conference papers
hal-01162711v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
P1266 : Human albumin use in cirrhotic patients in France: Results of the national “Albu-live” survey
A. Garioud
,
J. -F. Cadranel
,
A. Pauwels
,
T. Thevenot
,
A. Louvet
et al.
The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver , Apr 2015, Vienne, Austria. 62, Supplement 2, pp.S833, 2015,
⟨10.1016/S0168-8278(15)31461-6⟩
Conference poster
hal-01162774v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment a prospective cohort study
Fabrice Carrat
,
Hélène Fontaine
,
Céline Dorival
,
Mélanie Simony
,
Alpha Diallo
et al.
Journal articles
hal-02050395v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Epidemiological, clinical, biological and virological factors influencing the occurrence of hepatocellular carcinoma and validation of predictive scores in 317 HBV-related cirrhotic patients. Prospective study Cir-B nested in the ANRS CO12 CirVir cohort
Sepolene Brichler
,
Richard Layese
,
Valérie Bourcier
,
Carole Cagnot
,
Patrick Marcellin
et al.
Hepatology , 2016, 63 (1 SUPP), pp.898A--899A
Journal articles
hal-01414692v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study
Charlotte Costentin
,
Richard Layese
,
Valérie Bourcier
,
Carole Cagnot
,
Patrick Marcellin
et al.
Journal articles
hal-02648451v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort
Anne Laurain
,
Sophie Metivier
,
Georges Haour
,
Dominique Larrey
,
Céline Dorival
et al.
Journal articles
hal-02120879v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
EFFICACY AND SAFETY OF TREATMENT WITH BULEVIRTIDE IN CHRONIC HEPATITIS DELTA: PRELIMINARY RESULTS OF THE REAL LIFE ANRS HD EP01 BULEDELTA COHORT
Fabien Zoulim
,
Claire Fougerou
,
Roulot Marullo Dominique
,
Sophie Metivier
,
Victor de Ledinghen
et al.
Hepatology , 2022, 76 (Supp 1), pp.S221-S223
Journal articles
hal-03922586v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)
E. Rosenthal
,
C Fougerou-Leurent
,
A. Renault
,
Mp. Carrieri
,
F. Marcellin
et al.
Journal articles
hal-01740817v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study
Isabelle Poizot-Martin
,
Eric Bellissant
,
Rodolphe Garraffo
,
Philippe Colson
,
Lionel Piroth
et al.
Journal articles
hal-01299973v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs
Pierre Nahon
,
Richard Layese
,
Valérie Bourcier
,
Carole Cagnot
,
Patrick Marcellin
et al.
Journal articles
hal-02648450v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)
Jean-Claude Trinchet
,
Valérie Bourcier
,
Cendrine Chaffaut
,
Mohand Ait Ahmed
,
Setty Allam
et al.
Journal articles
hal-01201948v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication
Manon Allaire
,
Pierre Nahon
,
Richard Layese
,
Valérie Bourcier
,
Carole Cagnot
et al.
Journal articles
hal-02648452v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients
Stanislas Pol
,
Marc Bourlière
,
Sandy Lucier
,
Christophe Hézode
,
Céline Dorival
et al.
Journal articles
hal-01435007v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study
Victor de Ledinghen
,
Claire Laforest
,
Christophe Hezode
,
Stanislas Pol
,
Alain Renault
et al.
Journal articles
hal-01743768v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)
Pierre Nahon
,
Mathilde Lescat
,
Richard Layese
,
Valérie Bourcier
,
Nabila Talmat
et al.
Journal articles
hal-01225507v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)
Nathalie Ganne-Carrié
,
Richard Layese
,
Valérie Bourcier
,
Carole Cagnot
,
Patrick Marcellin
et al.
Journal articles
hal-01381662v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Marc Bourlière
,
Jean-Pierre Bronowicki
,
Victor de Ledinghen
,
Christophe Hézode
,
Fabien Zoulim
et al.
Journal articles
hal-01134440v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
P0768 : Late mortality in treatment-experienced cirrhotic patients treated with triple therapy including boceprevir or telaprevir in a real-life cohort - ANRS Co 20 cupic
J. -P. Bronowicki
,
H. Fontaine
,
C. Dufour
,
F. Zoulim
,
D. Larrey
et al.
The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver , Apr 2015, Vienne, Austria. 62, Supplement 2, pp.S617--S618, 2015,
⟨10.1016/S0168-8278(15)30971-5⟩
Conference poster
hal-01162777v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather
H. Fontaine
,
C. Hezode
,
F. Zoulim
,
D. Samuel
,
M. Bourlière
et al.
The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver , Apr 2015, Vienne, Austria. 62, Supplement 2, pp.S278, 2015,
⟨10.1016/S0168-8278(15)30182-3⟩
Conference poster
hal-01162770v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Real life study of bulevirtide in chronic hepatitis delta: preliminary results of the ANRS HD EP01 BuleDelta prospective cohort
Hélène Fontaine
,
Claire Fougerou-Leurent
,
Emmanuel Gordien
,
Caroline Scholtès
,
Sophie Métivier
et al.
Journal of Hepatology , 2022, 77, pp.S72-S72
Journal articles
hal-03770282v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Predictive Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Using Structural Equation Modeling: A Prospective Cohort Study
Laurent Lam
,
Hélène Fontaine
,
Marc Bourliere
,
Clovis Lusivika-Nzinga
,
Céline Dorival
et al.
Journal articles
hal-03224103v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?
Audrey Coilly
,
Jérôme Dumortier
,
Danielle Botta-Fridlund
,
Marianne Latournerie
,
Vincent Leroy
et al.
Journal articles
hal-01326372v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890
Christophe Hézode
,
Hélène Fontaine
,
Céline Dorival
,
Dominique Larrey
,
Fabien Zoulim
et al.
Journal articles
hal-01708037v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?
Lucy Meunier
,
Mohamed Belkacemi
,
George Philippe Pageaux
,
Sylvie Radenne
,
Anaïs Vallet-Pichard
et al.
Journal articles
hal-03980202v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
Eric Lawitz
,
Edward Gane
,
Brian Pearlman
,
Edward Tam
,
Wayne Ghesquiere
et al.
Journal articles
hal-01142117v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Efficacy and safety of MK-5172 and MK-8742 +/- ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null response: Final results of the C-WORTHY Study (Parts A and B)
Eric Lawitz
,
Edward J. Gane
,
Brian Pearlman
,
Edward Tam
,
Wayne Ghesquiere
et al.
65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases , Nov 2014, Boston, United States
Conference papers
hal-03252092v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study
Charlotte Costentin
,
Richard Layese
,
Valérie Bourcier
,
Carole Cagnot
,
Patrick Marcellin
et al.
Journal articles
hal-04075104v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More